

February 12, 2026

For Immediate Release

OrganTech. Inc.

OrganTech Presents at Morning Pitch

— Showcasing Medical Applications of Its Organ Regeneration Technology —

OrganTech. Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Yoshio Shimo; hereinafter “OrganTech”), a company dedicated to the medical application of the world’s first organ regeneration technology*, participated in the “573rd Most Promising Investment Sectors Attracting High-Net-Worth Capital” Morning Pitch event, held on Thursday, February 12, 2026. The event was hosted by Deloitte Tohmatsu Venture Support Co., Ltd. and Nomura Securities Co., Ltd.

At the event, OrganTech’s Chief Technology Officer, Miho Ogawa, took the stage on behalf of the company.

Morning Pitch is a weekly pitch event held every Thursday at 7:00 a.m., aimed at fostering business collaborations between venture companies and large corporations. Each week, five venture companies present to an audience of approximately 150 participants, including representatives from major corporations, venture capital firms, financial institutions, media organizations, and local governments. Since its launch in January 2013, approximately 3,000 venture companies have presented at Morning Pitch.



During her presentation, Ogawa introduced several application examples of OrganTech’s organ regeneration technology. These included the company’s R&D progress toward the

social implementation of its “Next-Generation Bio-Implant Project,” which aims to regenerate teeth, as well as its “Hair Regenerative Medicine Project.” She also explained OrganTech’s R&D support services for healthcare companies utilizing three-dimensional artificial skin.

The audience showed strong interest in OrganTech’s technology and business, raising numerous questions regarding the expected timing and locations for the launch of treatment services, as well as the rationale for prioritizing the U.S. market in overseas expansion.

OrganTech is also advancing global deployment with the goal of bringing Next-generation Bio-implants into practical use. Through business partnership opportunities such as Morning Pitch, the company will continue proactive information dissemination and, through R&D in medical devices and regenerative medicine, contribute to the creation of new high value-added industries, the improvement of quality of life, and the realization of a healthy longevity society.

*About Organ Regeneration Technology :

Almost all organs develop only once during the fetal stage from organ germs composed of epithelial stem cells and mesenchymal stem cells. The formation of fully functional mature organs proceeds through complex molecular signaling interactions between these two cell populations.

In 2007, OrganTech’s Chairman, Takashi Tsuji, was the first in the world to develop a method to reconstitute organ germs by isolating epithelial stem cells and mesenchymal stem cells and reassembling them at high density (Nature Methods, 2007). This technology, known as the “Organ Germ Method,” has demonstrated functional regeneration of organs such as teeth, hair follicles, salivary glands, and lacrimal glands.

Contact

Public Relations Office

OrganTech. Inc.

Harumi Center Building 6F, 2-5-24 Harumi, Chuo-ku, Tokyo 104-0053, Japan

TEL: +81-3-5859-5761

E-mail: info@organ-tech.jp

Website: <https://www.organ-tech.jp/>